Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2011
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb; Roche
- 06 Aug 2011 New trial record
- 01 Aug 2011 Results published in the Diabetes, Obesity and Metabolism.